Literature DB >> 25031184

Anatomical specificity of O6-methylguanine DNA methyltransferase protein expression in glioblastomas.

Yinyan Wang1, Xing Fan, Chuanbao Zhang, Tan Zhang, Xiaoxia Peng, Shaowu Li, Lei Wang, Jun Ma, Tao Jiang.   

Abstract

O6-methylguanine DNA methyltransferase (MGMT) is one of the important tumor-related biomarkers and is considered to be a prognostic factor for glioblastoma. This study aimed to investigate the anatomical location of tumor-related MGMT protein expression in histologically confirmed de novo glioblastoma multiforme (GBM). Preoperative magnetic resonance images were retrospectively examined from GBM patients. Tumor tissues were manually segmented based on the structural image of each patient and subsequently registered to a standard brain atlas. Superimposition of the tumor tissues was carried out in patients with and without epigenetic changes. We used voxel-based lesion symptom mapping (VLSM) to identify the specific brain regions that were associated with level of MGMT protein expression. The tumors with low expression of MGMT protein and those with high expression of MGMT protein showed not significant differences in tumor size on T2 imaging. The VLSM analysis demonstrated that tumors with low expression of MGMT protein were more likely to occur in the right temporal-parietal lobe, while tumors with high expression of MGMT protein occurred more often in the left frontal lobe. Based upon VLSM data, our results suggest that the epigenetic changes, which occur during tumorigenesis, may have anatomical specificity. The identified correlation between molecular biomarkers and anatomical distribution underscores the current understanding of the biological characteristics of glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25031184     DOI: 10.1007/s11060-014-1555-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

Review 1.  Brain tumors.

Authors:  L M DeAngelis
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

2.  Voxel-based lesion-symptom mapping.

Authors:  Elizabeth Bates; Stephen M Wilson; Ayse Pinar Saygin; Frederic Dick; Martin I Sereno; Robert T Knight; Nina F Dronkers
Journal:  Nat Neurosci       Date:  2003-05       Impact factor: 24.884

3.  Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Whitney B Pope; Taryar M Zaw; Heidi Phillips; Shadi Lalezari; Phioanh L Nghiemphu; Hassana Ibrahim; Kourosh M Naeini; Robert J Harris; Albert Lai
Journal:  Neuroimage       Date:  2011-10-07       Impact factor: 6.556

4.  Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations.

Authors:  Wei Zhang; Xiao-guang Qiu; Bao-shi Chen; Shou-wei Li; Yun Cui; Huan Ren; Tao Jiang
Journal:  Chin Med J (Engl)       Date:  2009-06-05       Impact factor: 2.628

5.  Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.

Authors:  M C Zlatescu; A TehraniYazdi; H Sasaki; J F Megyesi; R A Betensky; D N Louis; J G Cairncross
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

Review 6.  MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Authors:  Michael Weller; Roger Stupp; Guido Reifenberger; Alba A Brandes; Martin J van den Bent; Wolfgang Wick; Monika E Hegi
Journal:  Nat Rev Neurol       Date:  2009-12-08       Impact factor: 42.937

7.  Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2.

Authors:  Marc R J Carlson; Whitney B Pope; Steve Horvath; Jerome G Braunstein; Phioanh Nghiemphu; Cho-Lea Tso; Ingo Mellinghoff; Albert Lai; Linda M Liau; Paul S Mischel; Jun Dong; Stanley F Nelson; Timothy F Cloughesy
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

8.  Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis.

Authors:  Whitney B Pope; Jenny H Chen; Jun Dong; Marc R J Carlson; Alla Perlina; Timothy F Cloughesy; Linda M Liau; Paul S Mischel; Phioanh Nghiemphu; Albert Lai; Stanley F Nelson
Journal:  Radiology       Date:  2008-10       Impact factor: 11.105

Review 9.  Prognostic markers in gliomas.

Authors:  Marianne Labussiere; Xiao-Wei Wang; Ahmed Idbaih; François Ducray; Marc Sanson
Journal:  Future Oncol       Date:  2010-05       Impact factor: 3.674

10.  Early asymmetry of gene transcription in embryonic human left and right cerebral cortex.

Authors:  Tao Sun; Christina Patoine; Amir Abu-Khalil; Jane Visvader; Eleanor Sum; Timothy J Cherry; Stuart H Orkin; Daniel H Geschwind; Christopher A Walsh
Journal:  Science       Date:  2005-05-12       Impact factor: 47.728

View more
  11 in total

1.  Pre-treatment neutrophils count as a prognostic marker to predict chemotherapeutic response and survival outcomes in glioma: a single-center analysis of 288 cases.

Authors:  Zhiliang Wang; Liyun Zhong; Guanzhang Li; Ruoyu Huang; Qiangwei Wang; Zheng Wang; Chuanbao Zhang; Baoshi Chen; Tao Jiang; Wei Zhang
Journal:  Am J Transl Res       Date:  2020-01-15       Impact factor: 4.060

2.  Impact of removed tumor volume and location on patient outcome in glioblastoma.

Authors:  Al-Wala Awad; Michael Karsy; Nader Sanai; Robert Spetzler; Yue Zhang; Yizhe Xu; Mark A Mahan
Journal:  J Neurooncol       Date:  2017-07-06       Impact factor: 4.130

3.  Age-associated brain regions in gliomas: a volumetric analysis.

Authors:  Yinyan Wang; Shuai Liu; Xing Fan; Shaowu Li; Renzhi Wang; Lei Wang; Jun Ma; Tao Jiang; Wenbin Ma
Journal:  J Neurooncol       Date:  2015-05-16       Impact factor: 4.130

4.  Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival.

Authors:  Shristi Butta; Manoj Kumar Gupta
Journal:  Med Pharm Rep       Date:  2021-07-29

5.  IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.

Authors:  Amélie Darlix; Jérémy Deverdun; Nicolas Menjot de Champfleur; Florence Castan; Sonia Zouaoui; Valérie Rigau; Michel Fabbro; Yordanka Yordanova; Emmanuelle Le Bars; Luc Bauchet; Catherine Gozé; Hugues Duffau
Journal:  J Neurooncol       Date:  2017-04-22       Impact factor: 4.130

6.  Anatomical specificity of vascular endothelial growth factor expression in glioblastomas: a voxel-based mapping analysis.

Authors:  Xing Fan; Yinyan Wang; Kai Wang; Shuai Liu; Yong Liu; Jun Ma; Shaowu Li; Tao Jiang
Journal:  Neuroradiology       Date:  2015-10-09       Impact factor: 2.804

7.  Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics.

Authors:  Naeim Bahrami; Stephen J Hartman; Yu-Hsuan Chang; Rachel Delfanti; Nathan S White; Roshan Karunamuni; Tyler M Seibert; Anders M Dale; Jona A Hattangadi-Gluth; David Piccioni; Nikdokht Farid; Carrie R McDonald
Journal:  J Neurooncol       Date:  2018-06-02       Impact factor: 4.130

8.  Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas.

Authors:  Xing Fan; Yinyan Wang; Yong Liu; Xing Liu; Chuanbao Zhang; Lei Wang; Shaowu Li; Jun Ma; Tao Jiang
Journal:  J Neurooncol       Date:  2016-05-27       Impact factor: 4.506

9.  Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors.

Authors:  Jinquan Cai; Jing Chen; Wei Zhang; Pei Yang; Chuanbao Zhang; Mingyang Li; Kun Yao; Hongjun Wang; Qingbin Li; Chuanlu Jiang; Tao Jiang
Journal:  Oncotarget       Date:  2015-07-20

10.  Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation.

Authors:  Fatih Incekara; Sebastian R van der Voort; Hendrikus J Dubbink; Peggy N Atmodimedjo; Rishi Nandoe Tewarie; Geert Lycklama; Arnaud J P E Vincent; Johan M Kros; Stefan Klein; Martin van den Bent; Marion Smits
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.